Microbot Medical’s LIBERTY System Gains Traction as CEO Takes Center Stage at Surgical Innovation Summit
Event summary
- Microbot Medical’s CEO Harel Gadot to feature as panelist at The Surgical Disruptive Technology Summit, February 19-21, 2026.
- LIBERTY System highlighted in 'Endovascular Therapeutics: AI and Robotics' panel, positioning it as a new category in surgical robotics.
- Company plans full market release of LIBERTY at Society of Interventional Radiology (SIR) conference in April 2026.
- LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
The big picture
Microbot Medical’s LIBERTY System is gaining visibility as the company positions it as a disruptive force in endovascular procedures. The focus on AI and robotics aligns with broader industry trends toward minimally invasive interventions, potentially expanding access to advanced robotic care. The upcoming full market release at the SIR conference in April 2026 will be a critical milestone in assessing the system’s commercial viability.
What we're watching
- Market Adoption
- The pace at which LIBERTY gains traction post-full market release in April 2026.
- Regulatory Dynamics
- Whether FDA clearance and single-use design will accelerate broader adoption in vascular care.
- Competitive Positioning
- How LIBERTY’s unique features will differentiate it in the evolving surgical robotics market.
Related topics